Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T in Refractory Autoimmune Diseases
NCT05239702Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD7-CART in Crohn's disease, ulcerative colitis (UC), dermatomyositis (DM) and 2 more (5 arms), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 2 years. Status: unknown.
02
Drugs
CD7-CART
03
Conditions
Crohn's diseaseulcerative colitis (UC)dermatomyositis (DM)adult-onset Still's disease (AOSD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05239702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239702.